Cited by

• Application of industry 4.0 technology in containing Covid-19 spread and its challenges.

  Paranitharan KP, Ebenezer G, Balaji V, Adham Khan M, Ramesh Babu T. Paranitharan KP, et al. Mater Today Proc. 2022;68:1225-1232. doi: 10.1016/j.matpr.2022.06.009. Epub 2022 Jun 6. Mater Today Proc. 2022. PMID: 35692256 Free PMC article.
• Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.

  Pereira-Silva M, Chauhan G, Shin MD, Hoskins C, Madou MJ, Martinez-Chapa SO, Steinmetz NF, Veiga F, Paiva-Santos AC. Pereira-Silva M, et al. Expert Opin Drug Deliv. 2021 Oct;18(10):1395-1414. doi: 10.1080/17425247.2021.1922387. Epub 2021 Jun 6. Expert Opin Drug Deliv. 2021. PMID: 33944644 Free PMC article.
• Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.

  Rozzo G, Ramondetta A, Fierro MT, Dapavo P, Ribero S. Rozzo G, et al. Dermatol Ther. 2020 Jul;33(4):e13680. doi: 10.1111/dth.13680. Epub 2020 Jun 18. Dermatol Ther. 2020. PMID: 32447800 Free PMC article. No abstract available.
• Evaluation of three immunochromatographic tests in COVID-19 serologic diagnosis and their clinical usefulness.

  Pegoraro M, Militello V, Salvagno GL, Gaino S, Bassi A, Caloi C, Peretti A, Bizzego S, Poletto L, Bovo C, Lippi G, Lo Cascio G. Pegoraro M, et al. Eur J Clin Microbiol Infect Dis. 2021 Apr;40(4):897-900. doi: 10.1007/s10096-020-04040-1. Epub 2020 Oct 20. Eur J Clin Microbiol Infect Dis. 2021. PMID: 33078222 Free PMC article.
• Individual Differences, Economic Stability, and Fear of Contagion as Risk Factors for PTSD Symptoms in the COVID-19 Emergency.

  Di Crosta A, Palumbo R, Marchetti D, Ceccato I, La Malva P, Maiella R, Cipi M, Roma P, Mammarella N, Verrocchio MC, Di Domenico A. Di Crosta A, et al. Front Psychol. 2020 Sep 8;11:567367. doi: 10.3389/fpsyg.2020.567367. eCollection 2020. Front Psychol. 2020. PMID: 33013604 Free PMC article.